InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,454.89
(
0.13%
)
US TECH 100
19,054.00
(
0.50%
)
Dow Jones
39,345.50
(
-0.17%
)
Brent Oil
84.85
(
-0.50%
)
Bitcoin
61,113.84
(
1.41%
)
Post# of 144814
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bulldurham

Send PM Follow Ignore
Followers 35
Posts 1393
Boards Moderated 0
Alias Born 09/09/2009

bulldurham

Re: bulldurham post# 25823

Wednesday, 09/03/2014 3:06:42 PM

Wednesday, September 03, 2014 3:06:42 PM

Post# of 144814
Since we are already using Bristol-Myers Squibb's Ifosfamide it would make perfect sense that we would be using Bristol-Myers Squibb's Paraplatin Injection for the Von Hoff TD2 study...since that is the original drug not the generic for ovarian cancer... and since we have a relationship there already...


go Nuvilex
bull
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent PMCB News
More PMCB News
InvestorsHub NewsWire

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM

Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM

ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM

Start posting your company's news
Only $200 per official company press release!